Merck & Co., Inc: Carcinoma, Hepatocellular trials
The registry lists 14 Carcinoma, Hepatocellular studies with Merck & Co., Inc as lead sponsor. 0 are open to participants now and 11 have results posted.
Phase 1 5Phase 2 5Phase 3 6(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)CompletedNCT05007106Phase 2Results posted
- Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)TerminatedNCT04246177Phase 3Results posted
- Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)CompletedNCT03867084Phase 3Results posted
- Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)CompletedNCT03713593Phase 3Results posted
- Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)CompletedNCT03062358Phase 3Results posted
- Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)CompletedNCT02702414Phase 2Results posted
- Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)CompletedNCT02702401Phase 3Results posted
- Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular CarcinomaCompletedNCT02024087Phase 1/2Results posted
- Characterization of Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma (MK-0000-215)TerminatedNCT01521780Phase 1Results posted
- An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) ProtocolsCompletedNCT01178411Phase 1/2Results posted
- Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)CompletedNCT00759109Phase 3Results posted
- Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid TumorsCompletedNCT00827177Phase 1
- Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)CompletedNCT00802555Phase 1
- Modified Process Hepatitis B Vaccine in Healthy Neonates (V232-056)CompletedNCT00322361Phase 2